What Is a Flare? The Manitoba Living With IBD Study.
IBD symptom inventory
disease activity
disease flare
fecal calprotectin
symptoms
Journal
Inflammatory bowel diseases
ISSN: 1536-4844
Titre abrégé: Inflamm Bowel Dis
Pays: England
ID NLM: 9508162
Informations de publication
Date de publication:
03 06 2022
03 06 2022
Historique:
received:
30
03
2021
pubmed:
5
8
2021
medline:
9
6
2022
entrez:
4
8
2021
Statut:
ppublish
Résumé
Flare is a poorly defined term used by patients and clinicians to indicate inflammatory bowel disease (IBD) status. This study aimed to evaluate the validity of a single-item 7-point flare indicator relative to other measures of disease flare. The longitudinal Manitoba Living with IBD Study followed persons with IBD for 1 year; they completed biweekly online surveys and provided 3 stool samples. Disease flare on a single-item flare indicator with 7 possible responses developed for the study was defined by report of symptoms as "moderately" or "much" worse. The flare indicator was evaluated against 5 measures of disease activity: fecal calprotectin score (FCAL), a 2-point disease status indicator, a 4-point flare certainty indicator, the IBD Symptom Index short form (SIBDSI), and the short form IBD Questionnaire (SIBDQ). Participants in a flare, based on the 7-point measure, were matched to a nonflaring participant, and a stool sample was collected. Of the 155 IBD participants, almost half (n = 74) experienced a flare. Of those who flared, 97.0% endorsed active IBD on the 2-point indicator (controls 42.5%; P < .001); 91.9% endorsed active IBD on the 4-point certainty indicator (controls 32.9%; P < .001); 90.5% endorsed active disease on the SIBDSI (controls 34.2%; P < .001); and 48.5% had an elevated FCAL (controls 34.3%; P < .05). The mean SIBDQ was lower for the flare group compared with controls (43.9 [SD 11.1] vs 58.3 [SD 8.5]; P < .001), indicating worse disease. The 7-point flare indicator robustly identified symptomatic flares. This patient self-report indicator reflected meaningful changes in more complex clinical indices and had only weak concordance with the presence of inflammation.
Sections du résumé
BACKGROUND
Flare is a poorly defined term used by patients and clinicians to indicate inflammatory bowel disease (IBD) status. This study aimed to evaluate the validity of a single-item 7-point flare indicator relative to other measures of disease flare.
METHODS
The longitudinal Manitoba Living with IBD Study followed persons with IBD for 1 year; they completed biweekly online surveys and provided 3 stool samples. Disease flare on a single-item flare indicator with 7 possible responses developed for the study was defined by report of symptoms as "moderately" or "much" worse. The flare indicator was evaluated against 5 measures of disease activity: fecal calprotectin score (FCAL), a 2-point disease status indicator, a 4-point flare certainty indicator, the IBD Symptom Index short form (SIBDSI), and the short form IBD Questionnaire (SIBDQ). Participants in a flare, based on the 7-point measure, were matched to a nonflaring participant, and a stool sample was collected.
RESULTS
Of the 155 IBD participants, almost half (n = 74) experienced a flare. Of those who flared, 97.0% endorsed active IBD on the 2-point indicator (controls 42.5%; P < .001); 91.9% endorsed active IBD on the 4-point certainty indicator (controls 32.9%; P < .001); 90.5% endorsed active disease on the SIBDSI (controls 34.2%; P < .001); and 48.5% had an elevated FCAL (controls 34.3%; P < .05). The mean SIBDQ was lower for the flare group compared with controls (43.9 [SD 11.1] vs 58.3 [SD 8.5]; P < .001), indicating worse disease.
CONCLUSIONS
The 7-point flare indicator robustly identified symptomatic flares. This patient self-report indicator reflected meaningful changes in more complex clinical indices and had only weak concordance with the presence of inflammation.
Identifiants
pubmed: 34347048
pii: 6339341
doi: 10.1093/ibd/izab192
pmc: PMC9165552
doi:
Substances chimiques
Leukocyte L1 Antigen Complex
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
862-869Subventions
Organisme : CIHR
Pays : Canada
Informations de copyright
© 2021 Crohn’s & Colitis Foundation. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Références
PLoS One. 2017 Jul 27;12(7):e0181435
pubmed: 28749985
Inflamm Bowel Dis. 2014 Mar;20(3):545-52
pubmed: 24407484
World J Gastroenterol. 2016 Jan 21;22(3):1017-33
pubmed: 26811644
Clin Mol Pathol. 1995 Oct;48(5):M278-84
pubmed: 16696022
Inflamm Bowel Dis. 2019 Jul 17;25(8):1277-1290
pubmed: 30918969
Gastroenterol Hepatol (N Y). 2011 Sep;7(9):592-601
pubmed: 22298998
Am J Gastroenterol. 1996 Aug;91(8):1571-8
pubmed: 8759664
Gastroenterol Clin North Am. 2012 Jun;41(2):483-95
pubmed: 22500530
Scand J Gastroenterol. 1978;13(7):833-7
pubmed: 364626
Eur J Gastroenterol Hepatol. 2009 May;21(5):558-64
pubmed: 19194304
Gastroenterology. 2007 Feb;132(2):763-86
pubmed: 17258735
J Crohns Colitis. 2013 Dec;7(12):e678-83
pubmed: 23845231
Am J Gastroenterol. 2009 Jul;104(7):1754-63
pubmed: 19455122
J Gastroenterol. 2018 Mar;53(3):305-353
pubmed: 29429045
JMIR Res Protoc. 2018 Nov 12;7(11):e11317
pubmed: 30425031
Inflamm Bowel Dis. 2010 Dec;16(12):2137-47
pubmed: 20848468
Clin Gastroenterol Hepatol. 2011 Sep;9(9):769-75
pubmed: 21645640
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
Am J Gastroenterol. 2010 Jan;105(1):162-9
pubmed: 19755969
Aliment Pharmacol Ther. 2011 Jul;34(2):113-24
pubmed: 21615435
Lancet. 1980 Mar 8;1(8167):514
pubmed: 6102236
Gastroenterology. 2002 Feb;122(2):512-30
pubmed: 11832465
Inflamm Bowel Dis. 2015 Apr;21(4):824-31
pubmed: 25738372
Inflamm Bowel Dis. 2014 Aug;20(8):1407-15
pubmed: 24983982
Am J Gastroenterol. 2010 Sep;105(9):1994-2002
pubmed: 20372115
J Crohns Colitis. 2017 Mar 1;11(suppl_2):S576-S585
pubmed: 27797917
J Clin Gastroenterol. 2021 Aug 1;55(7):602-608
pubmed: 32694264
Am J Gastroenterol. 2015 Jul;110(7):1001-12; quiz 1013
pubmed: 26077178